Published in Arch Intern Med on February 14, 2011
The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine (2012) 1.83
FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012. JAMA (2014) 1.70
Security and privacy qualities of medical devices: an analysis of FDA postmarket surveillance. PLoS One (2012) 1.40
How does medical device regulation perform in the United States and the European union? A systematic review. PLoS Med (2012) 1.24
Improving medical device regulation: the United States and Europe in perspective. Milbank Q (2014) 1.13
Joint registry approach for identification of outlier prostheses. Acta Orthop (2013) 1.04
Medical-device recalls in the UK and the device-regulation process: retrospective review of safety notices and alerts. BMJ Open (2011) 0.99
Regulatory approval of new medical devices: cross sectional study. BMJ (2016) 0.95
Prevalence and Perioperative Outcomes of Off-Label Total Hip and Knee Arthroplasty in the United States, 2000-2010. J Arthroplasty (2015) 0.93
Placing a price on medical device innovation: the example of total knee arthroplasty. PLoS One (2013) 0.88
Medical device recalls: get it right the first time: Comment on "Medical device recalls and the FDA approval process". Arch Intern Med (2011) 0.83
FDA recalls not as alarming as they seem. Arch Intern Med (2011) 0.83
Medical telerobotic systems: current status and future trends. Biomed Eng Online (2016) 0.82
Approval of high-risk medical devices in the US: implications for clinical cardiology. Curr Cardiol Rep (2014) 0.81
Medical device regulation: time to improve performance. PLoS Med (2012) 0.80
Regulatory reticence and medical devices. Milbank Q (2014) 0.78
FDA regulation of cardiovascular devices and opportunities for improvement. J Interv Card Electrophysiol (2012) 0.78
Contrasting clinical evidence for market authorisation of cardio-vascular devices in Europe and the USA: a systematic analysis of 10 devices based on Austrian pre-reimbursement assessments. BMC Cardiovasc Disord (2014) 0.76
FDA Policy and Cardiovascular Medicine. Circulation (2015) 0.75
Rethinking medical device regulation. J R Soc Med (2012) 0.75
More on device recalls. Arch Intern Med (2011) 0.75
A Disposable Tear Glucose Biosensor-Part 4: Preliminary Animal Model Study Assessing Efficacy, Safety, and Feasibility. J Diabetes Sci Technol (2014) 0.75
Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health. Milbank Q (2017) 0.75
Medical Device Recalls in Radiation Oncology: Analysis of US Food and Drug Administration Data, 2002-2015. Int J Radiat Oncol Biol Phys (2017) 0.75
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA (2009) 8.56
Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med (2009) 6.89
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol (2013) 4.72
Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med (2003) 4.61
Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation (2002) 4.31
Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol (2006) 3.54
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA (2007) 3.25
Incidence of traumatic brain injury in New Zealand: a population-based study. Lancet Neurol (2012) 3.12
Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol (2006) 2.76
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation (2008) 2.34
High-dose statins in acute coronary syndromes: not just lipid levels. JAMA (2004) 2.31
Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol (2006) 2.22
Left main trunk coronary artery dissection as a consequence of inaccurate coronary computed tomographic angiography. Arch Intern Med (2010) 2.21
Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol (2008) 2.08
Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol (2010) 2.05
The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med (2010) 1.98
Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol (2006) 1.87
Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation (2007) 1.85
Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr (2004) 1.84
Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol (2006) 1.84
Risk of oral infection with bovine spongiform encephalopathy agent in primates. Lancet (2005) 1.82
Infectious agent of sheep scrapie may persist in the environment for at least 16 years. J Gen Virol (2006) 1.77
The rise and fall of rosiglitazone. Eur Heart J (2010) 1.76
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol (2011) 1.71
Novel methods for disinfection of prion-contaminated medical devices. Lancet (2004) 1.68
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging (2014) 1.64
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol (2005) 1.59
Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol (2009) 1.58
Atypical BSE (BASE) transmitted from asymptomatic aging cattle to a primate. PLoS One (2008) 1.56
Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol (2010) 1.56
Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med (2007) 1.54
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA (2013) 1.54
Cardiovascular effects of diabetes drugs: emerging from the dark ages. Ann Intern Med (2012) 1.54
Limitations of computed tomography coronary angiography. J Am Coll Cardiol (2008) 1.52
Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter. Transfusion (2005) 1.51
Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. J Am Coll Cardiol (2002) 1.50
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J (2013) 1.49
Adverse clinical events during intrahospital transport by a specialized team: a preliminary report. Am J Crit Care (2011) 1.48
Static and serial assessments of coronary arterial remodeling are discordant: an intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am Heart J (2006) 1.48
Incidence of stroke in women in Auckland, New Zealand. Ethnic trends over two decades: 1981-2003. N Z Med J (2006) 1.48
Coronary imaging: angiography shows the stenosis, but IVUS, CT, and MRI show the plaque. Cleve Clin J Med (2003) 1.47
Sources of satisfaction and dissatisfaction among specialists within the public and private health sectors. N Z Med J (2013) 1.43
Intravascular ultrasonography: using imaging end points in coronary atherosclerosis trials. Cleve Clin J Med (2005) 1.43
Influence of coronary pulsation on volumetric intravascular ultrasound measurements performed without ECG-gating. Validation in vessel segments with minimal disease. Int J Cardiovasc Imaging (2003) 1.43
The editor's roundtable: atherosclerosis regression. Am J Cardiol (2008) 1.42
Cardiogenic shock in the setting of severe aortic stenosis: role of intra-aortic balloon pump support. Heart (2010) 1.40
Validation of an automated system for luminal and medial-adventitial border detection in three-dimensional intravascular ultrasound. Int J Cardiovasc Imaging (2003) 1.40
Pharmacogenomics and clopidogrel: irrational exuberance? JAMA (2011) 1.40
A prion lexicon (out of control). Lancet (2005) 1.25
Ontogenetic switches from plant resistance to tolerance: minimizing costs with age? Ecol Lett (2007) 1.23
Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion (2003) 1.23
Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol (2006) 1.21
Role of a medical social worker in improving quality of life for patients with advanced cancer with a structured multidisciplinary intervention. J Psychosoc Oncol (2007) 1.19
Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion (2002) 1.18
Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insights from serial intravascular ultrasound. J Am Coll Cardiol (2012) 1.17
Neuronal cell death in transmissible spongiform encephalopathies (prion diseases) revisited: from apoptosis to autophagy. Int J Biochem Cell Biol (2004) 1.17
Skin and soft tissue infections and vascular disease among drug users, England. Emerg Infect Dis (2007) 1.17
In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med (2003) 1.17
Autophagy is a part of ultrastructural synaptic pathology in Creutzfeldt-Jakob disease: a brain biopsy study. Int J Biochem Cell Biol (2004) 1.16
Non-invasive assessment of plaque morphology and remodeling in mildly stenotic coronary segments: comparison of 16-slice computed tomography and intravascular ultrasound. Coron Artery Dis (2003) 1.15
An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). J Interv Cardiol (2010) 1.14
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation (2006) 1.14
Trends in admissions to hospital involving an assault using a knife or other sharp instrument, England, 1997-2005. J Public Health (Oxf) (2007) 1.13
Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet (2003) 1.13
Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol (2013) 1.12
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol (2013) 1.08
Protein-protein interfaces: properties, preferences, and projections. J Proteome Res (2007) 1.08
Noninvasive imaging of coronary arteries: current and future role of multi-detector row CT. Radiology (2004) 1.07
Spontaneous mutations in the prion protein gene causing transmissible spongiform encephalopathy. Ann Neurol (2002) 1.07
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol (2008) 1.06
Therapeutic exercise during outpatient radiation therapy for advanced cancer: Feasibility and impact on physical well-being. Am J Phys Med Rehabil (2010) 1.06
Long-term neuropsychological and functional outcomes in stroke survivors: current evidence and perspectives for new research. Int J Stroke (2008) 1.05
Rate of progression of coronary atherosclerotic plaque in women. J Am Coll Cardiol (2007) 1.03
Experimental validation of the docking orientation of Cdc25 with its Cdk2-CycA protein substrate. Biochemistry (2005) 1.03
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol (2008) 1.01
Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology (2008) 1.01
Multiorgan detection and characterization of protease-resistant prion protein in a case of variant CJD examined in the United States. PLoS One (2010) 1.00
Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol (2011) 1.00
Changes in employment and household income during the 24 months following a cancer diagnosis. Support Care Cancer (2008) 0.99
Pathological prion protein in muscles of hamsters and mice infected with rodent-adapted BSE or vCJD. J Gen Virol (2006) 0.97
Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clin Ther (2009) 0.97
When health policy and empirical evidence collide: the case of cigarette package warning labels and economic consumer surplus. Am J Public Health (2013) 0.96
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther (2012) 0.95